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Context: Breast development is a key feature of feminization and therefore important to trans-
women (male-to-female transgender persons). It is not exactly known when breast development
starts after initiating cross-sex hormone therapy (CHT) and how much growth may be expected.
Objective: To investigate breast development in transwomen during their first year of CHT and
whether clinical or laboratory parameters predict breast development.
Design: This study was performed as part of the European Network for the Investigation of Gender
Incongruence, which is a prospective multicenter cohort study.
Setting: Gender clinics in Amsterdam, Ghent, and Florence.
Participants: Transwomen who completed the first year of CHT (n = 229).
Intervention: CHT.
Main Outcome Measures: Breast development in centimeter and cup size.
Results: The median age of the included transwomen was 28 years (range, 18 to 69). Mean breast-
chest difference increased to 7.96 3.1 cm after 1 year of CHT, mainly resulting in less than an AAA
cup size (48.7%). Main breast development occurred in the first 6 months of therapy. Serum
estradiol levels did not predict breast development after 1 year of CHT (first quartile, 3.6 cm [95%
confidence interval (CI), 2.7 to 4.5], second quartile, 3.2 cm [95% CI, 2.3 to 4.2], third quartile, 4.4 cm
[95% CI, 3.5 to 5.3], and fourth quartile, 3.6 cm [95% CI, 2.7 to 4.5]).
Conclusion: This study shows that, after 1 year of CHT, breast development is modest and occurs
primarily in the first 6 months. No clinical or laboratory parameters were found that predict breast
development. (J Clin Endocrinol Metab 103: 532–538, 2018)
Persons diagnosedwith gender dysphoria can be treatedwith cross-sex hormones to reduce distress and induce
desired physical changes. In transwomen (male-to-female
transgender persons) treatment consists of antiandrogens
and estrogens. Physical changes induced by this treatment
include breast development, reduced sperm production,
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reduced number of spontaneous erections, and changes
in body hair and body composition (1, 2), leading to
feminization.
Breast development is a key feature of feminization
and therefore important to transwomen. The Clinical
Practice Guidelines of the Endocrine Society indicate that
breast development starts 3 to 6 months after start of
cross-sex hormone therapy (CHT). The maximum effect
may be expected after 2 to 3 years of CHT (1). However,
because these time frames are estimated and not based
on clinical data, it is not exactly known when breast
development starts after induction of CHT. Besides, the
literature is inconsistent about howmuch growth may be
expected from CHT alone. The few studies addressing
this issue showed modest breast development after CHT
(3–5).Moreover, because of anatomical differences in the
male chest compared with the female chest, breast size
may appear smaller than the actual objectively measured
volume (6). Consequently, 60% to70%of all transwomen
seek additional breast augmentation besides CHT (7, 8).
Because a small portion of women with silicone breast
implants have local and/or systemic health complaints (9),
it is important to gain more knowledge about breast de-
velopment in transwomen to be able to reduce the number
of breast augmentations in this population.
Therefore, this study aims to prospectively examine the
absolute breast development in centimeters and bra cup
sizes in transwomen during their first year of CHT. Fur-
thermore, it will be studied whether age, weight change,
body mass index (BMI), smoking, treatment regimen, or
serum hormone levels influence breast development.
Subjects and Methods
Study population
This study was performed as part of the EuropeanNetwork
for the Investigation of Gender Incongruence (ENIGI) study
(10), a collaboration of four centers (Amsterdam, Florence,
Ghent, andOslo), to investigate the effects of CHT on different
parameters such as breast development. A detailed description
of the study design and protocol is described by Dekker et al.
(10). Briefly, persons were eligible for participation in the
ENIGI study if they were age 18 years or older, had a diagnosis
of gender dysphoria confirmed by a psychiatrist or psychol-
ogist, and were about to start CHT. Persons were not eligible if
they had ever used or were currently using cross-sex hor-
mones, if they were treated following a different protocol, or if
there was insufficient knowledge of the nation’s language.
Treatment of transwomen consisted of antiandrogens, with
either cyproterone acetate (10 to 100 mg daily) or spi-
ronolactone (100 to 150 mg daily), combined with adminis-
tration of estradiol valerate (2 to 6 mg daily), estradiol patches
(50 to 100 mcg/24 hours twice weekly), or estradiol gel (0.75
to 3 mg daily). Those older than age 40 were advised to use
estradiol transdermally to reduce the slightly increased risk of
thrombosis (11).
All transwomen included in the ENIGI study between 2010
and April 2016, who completed the first year of CHT and for
whom baseline breast and chest measurements were available,
were eligible for analyses. Because there were no breast and
chest measurements performed in the Oslo clinic, their partic-
ipants were omitted for analyses in this study. There were no
data available on serum hormone levels from the Florence clinic;
therefore, their patients were omitted for analyses including
laboratory data.
The overall study protocol was approved by the ethical
review board of Ghent University Hospital, Belgium. Of the
other participating centers, the local ethical review boards
approved participation to this study. Informed consent from
participants was obtained following institutional guidelines.
Data collection
In accordance with the study protocol, all persons were
evaluated every 3 months at the different outpatient clinics.
During physical examination, different circumference and length
measurements in centimeters and weight in kilograms were
registered. Breast circumference was measured in centimeters
with a tape measure horizontally placed around the thorax
over the fullest part of the bare breasts. Chest circumference
was measured with a tape measure horizontally placed around
the thorax in the inframammary fold (Fig. 1).
Laboratory tests
Blood samples were drawn at baseline, after 3 months, and
after 12 months of CHT. In Amsterdam, serum estradiol levels
were measured using a competitive immunoassay (Delfia;
PerkinElmer, Wallac Oy, Turku, Finland) with an interassay
coefficient of variation (CV) of , 13% and a lower limit of
quantitation (LOQ) of 20 pmol/L21 until July 2014. From July
2014, estradiol levels were measured using liquid chroma-
tography tandem mass spectometry (LC-MS/MS; VUmc,
Amsterdam, The Netherlands) with an interassay CV of,7%
and an LOQ of 20 pmol/L21. For analyses, Delfia values were
converted to LC-MS/MS values using the following formula:
LC-MS/MS = 1.60 3 Delfia 2 29. Until January 2013, serum
testosterone levels were measured using a radioimmunoassay
(RIA) (Coat-A-Count, Siemens, Los Angeles, CA; interassay
CV, ,10%; LOQ, 1 nmol L21). After January 2013, testos-
terone levels were measured using a competitive immunoassay
(Gen III, Architect, Abbott, Abbott Park, IL) with an interassay
CV ,10% and an LOQ of 0.1 nmol/L21. For analyses, RIA
values were converted to Architect values using the following
formulas: Architect = 1.1 3 RIA + 0.2 for levels ,8 nmol/L21
and Architect = 1.34 3 RIA 2 1.65 for levels .8 nmol/L21.
Luteinizing hormone (LH) was measured using an immuno-
metric assay (Architect) with an interassay CV ,6% and an
LOQ of 2 nmol/L21.
In Ghent, serum estradiol levels were measured using E170
Modular (E2Gen II, RocheDiagnostics,Mannheim,Germany),
until 19 March 2015. Thereafter, serum estradiol levels were
measured using E170Modular (E2 Gen III, Roche Diagnostics)
with an interassay CV of 3.2% and an LOQ of 92 pmol/L21.
For analyses, values measured before 19 March 2015 were
converted to Gen III values using the following formula: Gen
III = 6.687940 + 0.8344953Gen II. Serum testosterone levels
were measured using E170 Modular (E2 Gen II) with an
interassay CV of 2.6% and an LOQ of 0.4 nmol/L21. Serum LH
doi: 10.1210/jc.2017-01927 https://academic.oup.com/jcem 533
Downloaded from https://academic.oup.com/jcem/article-abstract/103/2/532/4642966
by Ghent University user
on 08 March 2018
levels were measured using E170 Modular (Roche Diagnostics)
with an interassay CV of 2.2% and an LOQ of 0.1 mIU/mL21.
Statistical analysis
First, the database was screened for missing, inconsistent,
and unreliable breast and chest values. Because of the overstated
inverted pyramid shape of the thorax, a greater chest than breast
circumference is highly unlikely. Consequently, all breast and
chest values resulting in a negative breast minus chest valuewere
replaced by a missing value assuming these were input mis-
takes (3.1%). Subsequently, all population- and individual-level
breast and/or chest circumference measurement outliers were
identified and replaced by a missing value (3.1%). Population
outliers were defined as mean 6 3 times the standard deviation
(SD). Individual-level outliers were identified using the method
described by Welch et al. (12), with a standardized residual
cutoff point of65. Last, all transwomenwith unknownbaseline
breast or chest measurements were removed from the database.
Baseline data are presented as mean with SD for normally
distributed data, and median with range for nonnormally dis-
tributed data. Data on tobacco use and alcohol use are presented
as percentage of users. To examine the breast growth, chest
circumference in centimeters was subtracted from breast cir-
cumference in centimeters separately for all visits. To analyze
the effect of CHT on breast growth during the first year of
therapy, mixed-model analyses were performed with observa-
tions clustered within patients within center (13). Nonnormally
distributed data were log-transformed before mixed-model
analyses were performed. Analyses were stratified to study
whether age, weight change, differences in BMI, tobacco use,
treatment regimen, and serum hormone levels influenced breast
development during the first year of CHT. Age was analyzed in
quartiles andweight change was divided in three groups (weight
loss, no weight change, and weight gain). Differences in BMI
were defined as normal weight (BMI , 25 kg/m2), overweight
(25 kg/m2 $ BMI . 30 kg/m2), and obese (BMI $ 30 kg/m2).
Analysis for tobacco use was stratified into smokers vs
nonsmokers. Because most transwomen (99%) in this study
received cyproterone acetate as antiandrogen treatment, no
analyses on treatment regimen other than oral vs transdermal
estradiol administration route could be performed. Persons
were included in this analysis if they had received the same
administration route for at least 9 months. Analysis for serum
estradiol levels was stratified for center-specific quartiles. An-
alyses for testosterone and LH levels were stratified in sup-
pressed (testosterone levels # 2 nmol/L, LH levels # 5 IU/L) vs
nonsuppressed (testosterone levels . 2 nmol/L, LH levels . 5
IU/L) based on local female reference values. All data are
presented as mean change in centimeters with 95% confidence
interval (CI). Breast-chest differences after 1 year of CHT were
translated into bra cup sizes following the method described by
Greenbaum et al. (14).
All analyses were performed using STATA Statistical Soft-
ware, version 13.1 (Statacorp, College Station, TX).
Results
Until April 2016, 926 persons were included in the ENIGI
study, of which 53.8% were transwomen. Persons who
were still in their first year of CHT, who were lost to
follow-up, or who had unknown baseline breast or chest
measurements were excluded for analyses. Finally, a total
of 229 transwomen were included for analyses (Fig. 2).
The median age before start of CHT was 28 years (range,
18 to 69 years). At baseline, the mean breast-chest dif-
ference was 4.16 2.9 cm. All characteristics of the study
group are summarized in Table 1. Persons who were
excluded for analyses did not differ in baseline charac-
teristics from those who were included.
Breast development predominantly occurred in the
first 6 months of CHT, with an increase of 1.8 cm (95%
CI, 1.4 to 2.3) over the first 3 months, and 1.3 cm (95%
CI, 0.9 to 1.8) over the following 3months. The change in
breast-chest difference over the last 6 months was only
0.5 cm [0.3 cm (95% CI, 20.2 to +0.8) between 6 and
9 months of CHT and 0.2 cm [95% CI, 20.3 to +0.7]
over the last 3 months (Fig. 3)]. Mean breast-chest dif-
ference increased 3.7 cm (95%CI, 3.3 to 4.2) from 4.16
2.9 cm at baseline to 7.9 6 3.1 cm after 1 year of CHT.
Mean breast development did not change after adjust-
ment for baseline breast-chest difference [4.1 cm (95%
CI, 3.4 to 4.7)]. After calculating mean breast-chest
difference into bra cup sizes, almost half of the trans-
women (48.7%) had a bra cup size of less than an AAA
cup after 1 year of CHT (Fig. 4). Furthermore, 52
transwomen (26.4%) had an AAA cup, 28 (14.2%) an
AA cup, 14 (7.1%) an A cup, and only 7 transwomen
(3.6%) gained a bra cup size larger than an A cup. As
shown in Fig. 5(a) and 5(b), breast development did not
Figure 1. Placement of the tape measure for circumference
measurements. For breast circumference measurement, the tape
measure was placed around the thorax over the fullest part of the
breast (dotted line) and for chest circumference measurement in the
inframammary fold (dashed-dotted line).
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vary in different age groups or between transwomen who
had no weight change, weight loss, or weight gain over
the study period. Although obese transwomen had a
greater breast-chest difference in the first 6 months of
CHT, total breast-chest difference after 12 months did
not differ among normal weight, overweight, and obese
transwomen [Fig. 5(c)]. There was no difference in breast
development between smokers and nonsmokers [Fig.
5(d)]. Transwomen treated with transdermal estradiol
had a faster increase in breast-chest difference until
6 months after initializing treatment. However, breast
development after 1 year of treatment did not differ
between oral and transdermal estradiol administration
[Fig. 5(e)].
Mean serum estradiol levels in the center-specific
quartiles were 110 pmol/L21 (first quartile), 184 pmol/
L21 (second quartile), 271 pmol/L21 (third quartile), and
452 pmol/L21 (fourth quartile) in Amsterdam, and 142
pmol/L21 (first quartile), 206 pmol/L21 (second quartile),
299 pmol/L21 (third quartile), and 567 pmol/L21 (fourth
quartile) in Ghent. Serum estradiol levels did not predict
breast development after 1 year of CHT [first quartile:
3.6 cm (95% CI, 2.7 to 4.5); second quartile: 3.2 cm
(95% CI, 2.3 to 4.2); third quartile: 4.4 (95% CI, 3.5 to
5.3); and fourth quartile: 3.6 cm (95% CI, 2.7 to 4.5);
Fig. 5(f)]. Because CHT induced suppression of serum
testosterone and LH levels in almost all transwomen
(testosterone: not suppressed in 7.9%; LH: not sup-
pressed in 1.3%), no analyses could be performed on
these data. Transwomen with an A cup size or larger did
not differ in baseline characteristics from transwomen
with a cup size smaller than an A cup.
Discussion
The current study shows amodest increase in breast-chest
difference after 1 year of CHT, mainly resulting in less
than an AAA bra cup size. Age, weight change, smoking,
BMI, serum estradiol levels, and estrogen administration
route did not predict total breast development after 1 year
of CHT.
This large multicenter cohort study shows slightly
less breast development than shown in previous studies
performed (3, 4, 11, 15). However, these previous
studies used other measurement methods (e.g., hemi-
circumference measurements) and bra cup sizes were
estimated or self-reported rather than translated or
calculated from circumference measurements. Moreover,
CHT duration in these studies is not always clearly re-
ported and varies widely (from 3 to 24 months) (3–5),
which makes comparison of these studies with the cur-
rent study difficult. This study found a bra cup size of
less than an AAA cup in 48.7% of transwomen. Only
10.7% had an A cup or larger after 1 year of CHT.
Because only breast and chest circumference were mea-
sured and converted into bra cup sizes, it was impossible
Figure 2. Flowchart of the inclusion of participants in the current study. Abbreviations: transmen, female-to-male transgender persons;
transwomen, male-to-female transgender persons.
Table 1. Characteristics of 229 Transwomen
Before CHT
Age, y 28 (18–69)
Ethnicity, % Caucasian 95.6
Height, cm 178.6 6 6.8
Weight, kg 72.3 (49.9–137.2)
BMI, kg/m2 22.7 (16.5–37.7)
Smoking, % yes 25.3
Alcohol use, % yes 46.0
Breast circumference, cm 92.9 6 9.3
Chest circumference, cm 88.8 6 8.9
Breast-chest difference, cm 4.1 6 2.9
Data are presented as mean 6 SD, median (range), or percentages.
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to calculate breast volumes in this study. Because cup size
consists of more than thorax circumferences alone and
breast shapes vary widely between different people, cup
sizes found in this study were probably underestimated.
Breast tissue consists of both epithelial components,
with ducts and lobules, and stromal elements, consisting
of adipose and fibrous connective tissue. The latter ac-
counts for the majority of the total breast volume. The fat
distribution of transwomen after 1 year of CHT is still
developing and is not yet similar to that of ciswomen
(women with the birth-assigned sex of a female who
identify themselves as female) (16). This may contribute
to the modest breast development measured in this study.
Another explanation for the modest breast development
found could be that exposition to high testosterone
during male puberty induces some structural changes
that inhibit breast development. There were transwomen
in this study who had substantial breast development
during the first year of therapy and had passed normal
male puberty.
An interesting finding is that main breast development
occurred in the first 6 months of CHT. The flattening of
the breast development curve in this study suggests no
further increase in breast-chest difference after the first
year of CHT. However, the maximum effect of CHT on
breast development may be expected after 2 to 3 years, as
also seen during pubertal development in girls (1, 5, 17).
Because the follow-up of the current study is 2 year, no
conclusions can be drawn on final breast development
induced by CHT. Moreover, a recent study by Fisher
et al. showed breast development to Tanner stage 3 after
2 years of CHT, which emphasize the need for studies
with longer follow-up (18).
Levy et al. state that transwomen with a higher BMI
seem to have better breast development (15). Moreover,
Coltman et al. showed that breast volumes in overweight
or obese ciswomenwere greater compared with ciswomen
with a normal weight BMI (19). However, the current
study found no differences in breast development in
different BMI categories, which may be due to the small
number of overweight (18.1%) and obese (8.3%) per-
sons in this study. Another possible explanation may be
that the overweight and obese transwomen in this study
were encouraged to lose weight during the first year of
CHT in view of surgical treatment thereafter. Further-
more, this study did not find any differences in char-
acteristics, treatment regimen, or serum estradiol levels
in transwomenwith a breast development of an A cup or
larger compared with transwomen with a development
of smaller than an A cup. Consequently, no clinical or
laboratory parameters were found to be predictive for
breast development in this study. Although an expla-
nation for the difference in breast development between
persons may be genetic variation (20, 21), further studies
are required.
Figure 3. Mean breast-chest difference in centimeters over duration of CHT in months. For each time point, the mean increase in centimeters
(dot) with 95% CI (bars) is shown. Data in the legend are shown as mean increase with 95% CI.
Figure 4. Gained bra cup sizes in 197 transwomen after 1 year of
CHT. Data are shown as percentage of transwomen per cup size.
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This study provides more insight in how much breast
development can be expected of CHTduring the first year
of therapy. Other strengths are the prospective, multi-
center design of the study and the large number of par-
ticipants with a wide range of age. Moreover, this study
had fixed measurement moments every 3 months with
relatively few missing values (12.1% of all breast and/or
chest measurements). However, this study has some
limitations as well. First, thorax circumferences were
used for estimation of breast development, which prob-
ably provide a less reliable reflection of the actual
breast development compared with volume measure-
ments. Pechter suggested a hemicircumference measure-
ment method to calculate bra cup sizes (22), which may
be a better estimator than thorax circumference mea-
surements (23). Furthermore, McGhee et al. showed
that respiration affects circumference measurements and,
consequently, cup size estimations up to four sizes dis-
crepancy (23). Because respiration was not standardized
in this study, measurements were likely to be affected by
the respiration of the transwomen measured and thereby
it probably affected the accuracy of the measurements.
On the other hand, because of the lack of standardiza-
tion, some values will be overestimated and some un-
derestimated resulting in an overall reliable mean. Second,
this study was performed during regular care; as a con-
sequence, participating centers were not always able
to collect all data needed because of limited resources.
Nevertheless, we had access to a large sample with rel-
atively few missing values. Third, all data regarding
other medication use, comorbidities, tobacco use, and
alcohol use were self-reported and therefore might be
incomplete. Last, this study only reported objective out-
comes of breast development. This however says nothing
about the satisfaction of transwomenwith the gained breast
development. Van de Grift et al. (24) showed that body
satisfaction increased with hormone treatment, but that in
transwomen who received breast augmentation surgery,
body satisfaction was higher. Moreover, transpersons with
high overall body dissatisfaction at baseline showed per-
sistent higher dissatisfaction after treatment. Future studies
should incorporate body and/or breast satisfaction scales to
relate the clinical observed breast development to the sat-
isfaction of the transwomen themselves.
In conclusion, this large multicenter cohort study
shows modest breast development after 1 year of CHT in
transwomen. No predictive markers in clinical and lab-
oratory parameters, including serum estradiol levels,
were identified. It would be interesting for future studies
to search for other parameters and study whether these
predict breast development in transwomen during CHT.
Studies with longer follow-up are needed to determine the
final breast development gained with CHT alone. Fur-
thermore, it would be worthwhile for future studies to
use volume measurements for examining hormonally
induced breast development in transwomen.
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